Abstract
Resistance to the clinically used platinum-based drugs cisplatin and carboplatin represents a major limitation to their clinical effectiveness. Using cisplatin-sensitive and-resistant human ovarian carcinoma cell lines previously characterized in terms of their major underlying mechanisms of resistance, we attempted to potentiate the cytotoxic effects of cisplatin and carboplatin using the clinically used antifungal agent amphotericin B (AmB). Using nontoxic concentrations of AmB (up to 15 μg/ml) and continuous exposure to cisplatin, a concentration-dependent selective potentiation (maximum of 3.2-fold) of cisplatin cytotoxicity was observed in two cisplatin-resistant cell lines (41 McisR6, acquired resistant, and HX/62, intrinsically resistant). In both these cisplatin-resistant cell lines, previous studies have shown resistance to be due primarily to reduced platinum uptake. Notably, no significant potentiation was observed in the parent 41M cell line, in the intrinsically resistant SKOV-3 cell line (where reduced drug accumulation plays only a partial role in determining resistance) or in a pair of cell lines (CH1 and its acquired-resistant variant CH1cisR6) where reduced drug uptake does not play any role in determining resistance. The potentiating effect of AmB was lower with carboplatin and not significant in all cell lines. Platinum uptake following a 2-h exposure of cells to cisplatin was enhanced 3.5-fold in 41McisR6 cells (producing platinum levels similar to those obtained in the parental line) and 1.7-fold in 41M cells by the concomitant exposure to AmB. These data indicate that the potentiation of cisplatin (and carboplatin) cytotoxicity by AmB is not due to a generalized membrane disruption, as effects were observed only in resistant lines where reduced drug transport was apparent. Moreover, AmB did not increase the cytotoxicity of JM216 [bis-acetatoammine(cyclohexylamine)dichloroplatinum (II)], a recently developed, more lipophilic orally active platinum drug, in the 41M/41McisR6 lines. JM216 has previously been shown to circumvent acquired cisplatin resistance due to decreased drug uptake. In vivo, however, using the HX/62 xenograft, AmB (at its maximum tolerated dose of 20 mg/kg; q7d×4 schedule) did not enhance the antitumour effect of carboplatin (at its maximum tolerated dose of 80 mg/kg; q7d×4 schedule).
Similar content being viewed by others
References
Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cell 2: 35
Atkinson AJ, Bennett JE (1978) Amphotericin B pharmacokinetics in human. Antimicrob Agents Chemother 13: 271
Borisova MP, Ermishkin LN, Silberstein AYA (1979) Mechanism of blockage of amphotericin B channels in a lipid bilayer. Biochim Biophys Acta 553: 450
Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S, Cannetta R (1990) Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature. In: Bunn P, Cannetta R, Ozols R, Rozencweig M (eds) Carboplatin: Current perspectives and future directions. W. B. Saunders, Philadelphia, p 133
Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171
Gore M, Fryatt I, Wiltshaw E, Dawson T, Robinson B, Calvert H (1989) Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 60: 767
Harrap KR (1985) Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 12 [Suppl A]: 21
Harrap KR, Jones M, Pollard LA, Siracky J, Kelland LR (1990) The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer agents. Ann Oncol 1: 65
Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR (1989) Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 59: 527
Hromas RA, Andrews PA, Murphy MP, Burns CP (1987) Glutathione depletion reverses cisplatin resistance in murine L1210 leukaemia cells. Cancer Lett 34: 9
Kelland LR, Jones M, Abel G, Valenti M, Gwynne JJ, Harrap KR (1992) Human ovarian carcinoma cell lines and companion xenografts: a disease orientated approach to new platinum anticancer drug development. Cancer Chemother Pharmacol 30: 43
Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR (1992) Mechanism-related circumvention of acquiredcis-diamminedichloroplatinum (II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum (IV) dicarboxylates. Cancer Res 52: 3857
Kikkawa F, Kojima M, Oguchi H, Maeda O, Ishikawa H, Tamakoshi K, Mizuno K, Kawai M, Suganuma N, Tomoda Y (1993) Potentiating effect of amphotericin B on five platinum anticancer drugs in humancis-diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells. Anticancer Res 13: 891
Kraker AJ, Moore CW (1988) Accumulation ofcis-diamminedichloroplatinum (II) and platinum analogues by platinum-resistant murine leukaemia cells in vitro. Cancer Res 48: 9
Loehrer PJ, Einhorn LH (1984) Cisplatin. Ann Intern Med 100: 704
Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 66: 1109
Lowry OH, Rosebrough MT, Fnarr AL, Randall RJ (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193: 265
Mangioni C, Bolis G, Percorelli S, Bragman K, Epis A, Favalli G, Gambino A, Landoni F, Presit M, Torri W, Vassena L, Zanaboni F, Marsoni S (1989) Randomised trial in ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 81: 1464
Mann SC, Andrews PA, Howell SB (1990) Short-termcis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 25: 236
Masuda H, Tanaka T, Kido A, Kusaba I (1991) Potentiation of cisplatin against sensitive and resistant human ovarian cancer cell lines by amphotericin B. Cancer J 4: 119
McKeage MJ, Kelland LR (1993) New platinum drugs. In: Neidle S, Waring MJ (eds) Molecular aspects of anticancer drug-DNA interactions. Macmillan, London, p 169
McKeage MJ, Mistry P, Ward J, Boxall FE, Loh SY, O'Neill C, Elis P, Kelland LR, Morgan SE, Murrer BA, Santabarbara P, Harrap KR, Judson IR (1993) Phase I study of orally administered ammine-diacetato-dichloro-(cyclohexylamine)-platinum (Pt) (IV) (p.o. JM216). Proc Am Soc Clin Oncol 12: A320
Medoff G, Valeriote F, Lynch RG, Schlessinger D, Kobayashi GS (1974) Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosurea against a transplantable AKR leukaemia. Cancer Res 34: 974
Medoff G, Valeriote F, Dieckman J (1981) Potentiation of anticancer agents by amphotericin B. J Natl Cancer Inst 67: 131
Medoff G, Brajtburg J, Kobayashi GS (1983) Antifungal agents useful in therapy of systemic fungal infections. Annu Rev Pharmacol Toxicol 23: 303
Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR (1991) The relationship between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64: 215
Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR (1992) Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyradichloro(cyclohexylamine)platinum (II) (JM221) in human ovarian carcinoma cell lines. Cancer Res 52: 6188
Morikage T, Bungo M, Inomata M, Yoshida M, Ohmori T, Fujiwara Y, Nishio K, Saijo N (1991) Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn J Cancer Res 82: 747
Morikage T, Ohmori T, Nishio K, Fujiwara Y, Takeda Y, Saijo N (1993) Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res 53: 3302
Ozols RF, Young RC (1984) Chemotherapy of ovarian cancer. Semin Oncol 11: 251
Presant CA, Valeriote F, Profitt R, Metter G (1981) Amphotericin B-interactions with nitrosourea and other antineoplastic agents. In: Prestayko AW, Crooke ST, Baker LH, Carter SK, Schein PS (eds) Nitrosoureas: current and new developments. Academic Press, New York, p 343
Sabra R, Branch RA (1990) Amphotericin B nephrotoxicity. Drug Safety 5: 94
Sculier JP, Coune A, Meunier F, Brassine C, Laduron C, Hallaert C, Collette N, Heymans C, Klastersky J (1988) Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 24: 527
Sculier JP, Delcroix C, Brassinne C, Laduron C, Hollaert C, Coune A (1989) Pharmacokinetics of amphotericin B entrapped into sonicated liposomes. J Liposome Res 1: 151
Teicher BA, Holden SA, Kelly MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, Frei E III (1987) Characterisation of a human squamous carcinoma cell line resistant tocis-diamminedichloroplatinum (II). Cancer Res 47: 388
Timmer-Bosscha H, Mulder NH, DeVries EGE (1992) Modulation ofcis-diamminedichloroplatinum (II) resistance: a review. Br J Cancer 66: 227
Author information
Authors and Affiliations
Additional information
This study was supported by grants to the Institute of Cancer Research from the Cancer Research Campaign and the Medical Research Council, the Johnson Matthey Technology Centre and Bristol Myers Squibb Oncology
Rights and permissions
About this article
Cite this article
Sharp, S.Y., Mistry, P., Valenti, M.R. et al. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and-resistant human ovarian carcinoma cell lines by amphotericin B. Cancer Chemother. Pharmacol. 35, 137–143 (1994). https://doi.org/10.1007/BF00686636
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686636